fbpx

Stay Informed. Stay Competitive with FREE Insights on the Stock Market, Dow 30 & Emerging Opportunities. Get Free Email Updates

Stay Competitive With Stock Market Updates!

Get Free Updates

INVO

INVO Bioscience

  ( )

Page Views : 216769

Analyst Ratings

 
Strong
Buy
Strong Buy
50%
Buy
50%
Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

vista's key points

  • INVO operates within the ~$15-$18 Billion global infertility industry growing ~8-10% annually.
  • INVO is commercializing the world's only in vivo Intravaginal Culture System (IVC), INVOcell®, an accessible, inclusive, and affordable treatment for patients diagnosed with infertility.
  • INVOcell is an FDA cleared patented medical device that is one of only 3 ways today that a couple that is struggling with infertility may choose to use to try to get pregnant and that offers a more economical and natural way to proceed.
  • INVOcell addresses key industry challenges regarding cost & capacity constraints of in vitro- fertilization (IVF).
  • INVOcell is positioned to serve a vastly underserved global market as ~+90% of infertile individuals go untreated exposing a significant unmet market opportunity.
  • INVO is pushing forward with a combined distribution, joint venture/partner model to establish INVO-only clinics to accelerate adoption of INVOcell and their business worldwide.
  • INVO established a U.S. commercialization agreement in January 2019 with Ferring Pharmaceuticals, a multi-national firm that controls ~80% of the world's fertility drug market.
  • INVO now has distribution agreements in place in 8 countries located within Africa, Asia, Europe and the Middle East & continues to seek further relationships worldwide.
  • INVO Is Establishing INVOcell dedicated clinics within the US Market in 2021 in Atlanta, Birmingham, & San Francisco to accelerate growth and adoption.
  • INVO is seeking to open first INVO-only clinic in Mexico 2H 2021 after receiving approval on March 1 by COFEPRIS to import INVOcell into Mexico.
  • INVO successfully conducted a public offering in November 2020, raising net proceeds of approximately $11.6 million at $3.20/share, while uplisting the company onto the NASDAQ market.
  • INVO a "low" or "tight float" with only 10,424,229 shares issued and outstanding as of March 31, 2021.

Click Here To Learn More

vista's key points

  • INVO operates within the ~$15-$18 Billion global infertility industry growing ~8-10% annually.
  • INVO is commercializing the world's only in vivo Intravaginal Culture System (IVC), INVOcell®, an accessible, inclusive, and affordable treatment for patients diagnosed with infertility.
  • INVOcell is an FDA cleared patented medical device that is one of only 3 ways today that a couple that is struggling with infertility may choose to use to try to get pregnant and that offers a more economical and natural way to proceed.
  • INVOcell addresses key industry challenges regarding cost & capacity constraints of in vitro- fertilization (IVF).
  • INVOcell is positioned to serve a vastly underserved global market as ~+90% of infertile individuals go untreated exposing a significant unmet market opportunity.
  • INVO is pushing forward with a combined distribution, joint venture/partner model to establish INVO-only clinics to accelerate adoption of INVOcell and their business worldwide.
  • INVO established a U.S. commercialization agreement in January 2019 with Ferring Pharmaceuticals, a multi-national firm that controls ~80% of the world's fertility drug market.
  • INVO now has distribution agreements in place in 8 countries located within Africa, Asia, Europe and the Middle East & continues to seek further relationships worldwide.
  • INVO Is Establishing INVOcell dedicated clinics within the US Market in 2021 in Atlanta, Birmingham, & San Francisco to accelerate growth and adoption.
  • INVO is seeking to open first INVO-only clinic in Mexico 2H 2021 after receiving approval on March 1 by COFEPRIS to import INVOcell into Mexico.
  • INVO successfully conducted a public offering in November 2020, raising net proceeds of approximately $11.6 million at $3.20/share, while uplisting the company onto the NASDAQ market.
  • INVO a "low" or "tight float" with only 10,424,229 shares issued and outstanding as of March 31, 2021.

Click Here To Learn More

company profile

 

vista's view

INVO Bioscience (INVO) is an emerging growth company that owns the INVOcell system, an FDA cleared patented medical device that is one of only 3 ways today that a couple that is struggling with infertility may choose to use to try to get pregnant and that offers a more economical...

Read More

exclusive content

 

Vista Partners creates exclusive content based on the ongoing research of companies included in the VP Watchlist.

vp watchlist

The VP Watchlist contains current coverage companies that deserve consideration for short term and long term portfolio additions.

Stay Informed. Stay Competitive with FREE Insights on the Stock Market, Dow 30 & Emerging Opportunities.

Get Free Email Updates